Pfizer Loses Hemophilia Gene Therapy Patent Row To UniQure
A London court held Friday that uniQure's patent covering hemophilia gene therapy is valid because the specific protein it uses is not obvious, and that Pfizer infringed the patent with the...To view the full article, register now.
Already a subscriber? Click here to view full article